

Yueqing Guan*, Guobin Zhou* and Weiqun Yang

An efficient approach to the key intermediate of rosuvastatin

Abstract: An efficient synthetic approach to the synthesis of the 5-pyrimidinecarbaldehyde **2**, which is the key intermediate of rosuvastatin, involves the aerobic oxidation of the 5-pyrimidinemethanol **1** in the presence of $\text{Co}(\text{NO}_3)_2$, dimethylglyoxime (DmgH_2), and 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) under mild reaction conditions. The method does not require the use of hazardous or expensive chemicals and is suitable for scale-up.

Keywords: aerobic oxidation; key intermediate; 5-pyrimidinecarbaldehyde; rosuvastatin.

***Corresponding authors:** Yueqing Guan, Department of Biological and Chemical Engineering, Taizhou Vocational and Technical College, Taizhou 318000, China, e-mail: yqguan@126.com; and Guobin Zhou, Department of Chemistry, Taizhou University, Taizhou 318000, China, e-mail: gbzhou_zju@126.com
Weiqun Yang: Department of Biological and Chemical Engineering, Taizhou Vocational and Technical College, Taizhou 318000, China

Introduction

Statins [1, 2] such as atorvastatin [3, 4] and rosuvastatin (Figure 1) [5, 6] are very effective inhibitors [7] of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR) and are the most powerful lipid-lowering agents in use for people with or at risk of cardiovascular disease [8]. Rosuvastatin [9] has been called a super statin because it appears to reduce low-density lipoprotein (LDL) cholesterol to a greater degree than competitors in its class without additional adverse effects. Rosuvastatin is approved for the treatment of elevated LDL cholesterol (dyslipidemia) [10], total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia).

A well-known key intermediate for the synthesis of rosuvastatin is 4-(4-fluorophenyl)-6-isopropyl-2-(*N*-methyl-methanesulfonamido)-5-pyrimidinecarbaldehyde (**2** in Scheme 1). Many methodologies [11–15] for the synthesis of compound **2** have been developed over the past

decade (Scheme 1). However, most of them have shortcomings, such as harsh conditions, use of expensive catalysts, long reaction time, unsatisfactory yields, and tedious work-up. We now report a greatly improved synthesis of **2**.

Results and discussion

Oxidation of alcohols to the corresponding aldehydes or ketones is of importance in fundamental research and industrial manufacturing. Developing new and efficient catalytic technologies for the selective aerobic oxidation of alcohols has attracted much attention because of the obvious advantages of dioxygen, such as abundance, low cost, and non-toxicity of the byproduct (H_2O) [16–19]. Our current research interest is focused on the development of the catalytic oxidation system for pharmaceuticals and their intermediates. In this report, we describe an efficient approach, which is based on the work of Jing et al. [20], to the synthesis of **2** by the aerobic oxidation of **1** (Scheme 1). The methodology of Jing was greatly expanded by us by using readily available and inexpensive reagents. To the best of our knowledge, this is the first example of the preparation of **2** by using the three-component catalytic system, namely cobalt nitrate/dimethylglyoxime/2,2,6,6-tetramethylpiperidine-1-oxyl, abbreviated as $[\text{Co}(\text{NO}_3)_2/\text{DmgH}_2/\text{TEMPO}]$. This methodology is amendable to scaling-up (Scheme 1).

The starting alcohol **1** was derived in high yield from 4-fluorobenzaldehyde as previously described [12]. The aerobic oxidation of **1** with 1.0 mol% of $\text{Co}(\text{NO}_3)_2$, 1.0 mol% of TEMPO, and 4.0 mol% of DmgH_2 proceeded smoothly in





Figure 1 Chemical structure of rosuvastatin.



Scheme 1 Synthesis of 4-(4-fluorophenyl)-6-isopropyl-2-(*N*-methyl-methanesulfonamido)-5-pyrimidinecarbaldehyde (**2**).

dichloromethane under 0.4 MPa pressure of O₂ at 70°C for 3 h. The desired product **2** was obtained in 96% yield. The method is suitable for scale-up.

Experimental

General commercially available chemicals were all reagent grade. Melting points (mp) were determined on a Buchi 535 capillary melting apparatus. The ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Mercury Plus Varian 400 spectrometer. ESI mass spectra were acquired on a Thermo Scientific LCQ spectrometer. IR spectra were determined on a Nicolet NEXUS-470 FT-IR spectrometer in KBr pellets.

Synthesis of 4-(4-fluorophenyl)-6-isopropyl-2-(*N*-methyl-methanesulfonamido)-5-pyrimidinemethanol (**1**)

This compound was obtained as a white solid by using the known procedure described previously [12]; yield 93%; purity 99.5% (HPLC); white solid; mp 131.9–132.8°C [ref. [14], mp 131.5°C (DSC onset) and 133.6°C (DSC peak)]; ¹H NMR (DMSO-*d*₆): δ 1.26 (d, 6H, *J* = 5.2 Hz), 3.45 (s, 3H), 3.65 (m, 4H), 4.4 (s, 2H), 7.37 (m, 2H), 7.86 (m, 2H); ¹³C NMR (DMSO-*d*₆): δ 177.7, 165.5, 164.4, 162.5, 157.8, 134.6, 132.1, 132.0, 122.5, 115.8, 115.6, 56.3, 42.1, 33.7, 31.2, 22.5; MS (ESI): *m/z* 354.1 ([*M*+H]⁺, 100), 355.1 ([*M*+2]⁺, 18), 356.6 ([*M*+3]⁺, 7), 376.0 ([*M*+Na]⁺, 10%); IR: ν 3537, 2935, 1597, 1546, 1510, 1365, 1325, 1228, 1143, 1120, 1001, 952, 854, 812 cm⁻¹.

Synthesis of 4-(4-fluorophenyl)-6-isopropyl-2-(*N*-methyl-methanesulfonamido)-5-pyrimidinecarbaldehyde (**2**)

A 100 mL autoclave reactor, equipped with an efficient mechanical stirrer, was charged with 35.34 g (0.10 mol) of **1**, 0.156 g of TEMPO (1.0 mol%), 0.183 g of Co(NO₃)₂ (1.0 mol%), 0.464 g of DmgH₂ (4.0 mol%), and 50 mL of dichloromethane. The pressure of O₂ in the sealed reactor was kept under 0.4 MPa for 3 h. During this period of time the atmosphere inside the reactor was refilled with fresh oxygen three times and the mixture was stirred and heated to 70°C. Then the mixture was cooled to room temperature and treated with dichloromethane (100 mL). Then the suspension was filtered and the clear filtrate was washed with water (150 mL) and a saturated aqueous solution of sodium chloride (100 mL). Concentration under reduced pressure followed by trituration of the residue with cyclohexane gave the desired compound **2** (yield 33.7 g, 96%) as a white solid; purity 99% (HPLC); mp 177.5–178.9°C [ref. [14], mp 178.2°C (DSC onset) and 179.1°C (DSC peak)]; ¹H NMR (CDCl₃): δ 1.33 (d, 6H, *J* = 5.2 Hz), 3.62 (s, 3H), 3.61 (s, 3H), 4.02 (m, 1H), 7.21 (m, 2H), 7.64 (m, 2H), 9.98 (s, 1H); ¹³C NMR (CDCl₃): δ 190.5, 179.1, 169.8, 165.5, 163.5, 158.8, 132.7, 132.6, 119.6, 116.1, 115.90, 42.5, 33.1, 32.1, 21.7; MS (ESI): *m/z* 352.2 ([*M*+H]⁺, 100), 353.2 ([*M*+2]⁺, 18), 354.1 ([*M*+3]⁺, 5%); IR: ν 2976, 1685, 1600, 1533, 1508, 1444, 1315, 1230, 1157, 1126, 956, 902, 854, 808, 779 cm⁻¹.

Acknowledgments: This work was supported by the Scientific Research Fund of Zhejiang Provincial Education Department (No. Y201329469), the Science and Technology Project of Taizhou (No. 131KY07), and the Research Foundation for Post-doctoral Scientists of Taizhou (No. 2013BSH01).

Received October 13, 2013; accepted November 11, 2013; previously published online January 10, 2014

References

- [1] Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. *Nat. Rev. Drug Discov.* **2003**, 2, 517–526.
- [2] Casar, Z. Historic overview and recent advances in the synthesis of super-statins. *Curr. Org. Chem.* **2010**, 14, 816–845.
- [3] Tararov, V. I.; König, G.; Börner, A. Synthesis and highly stereoselective hydrogenation of the statin precursor ethyl (5S)-5,6-isopropylidenedioxy-3-oxohexanoate. *Adv. Synth. Catal.* **2006**, 348, 2633–2644.
- [4] Tararov, V. I.; Andrushko, N.; Andrushko, V.; König, G.; Spannenberg, A.; Börner, A. Synthesis of the chiral side chain of statins-lactone versus lactol pathway. *Eur. J. Org. Chem.* **2006**, 24, 5543–5550.
- [5] Watanabe, M.; Koike, H.; Ishiba, T.; Okada, T.; Seo, S.; Hirai, K. Synthesis and biological activity of methanesulfonamide pyrimidine- and *N*-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase Inhibitors. *Bioorg. Med. Chem.* **1997**, 5, 437–444.
- [6] Casar, Z.; Steinbücher, M.; Kosmrlj, J. Lactone pathway to statins utilizing the Wittig reaction. The synthesis of rosuvastatin. *J. Org. Chem.* **2010**, 75, 6681–6684.
- [7] Soran, H.; Durrington, P. Rosuvastatin: efficacy, safety and clinical effectiveness. *Expert Opin. Pharmacother.* **2008**, 9, 2145–2160.
- [8] Kidd, J. Life after statin patent expires. *Nat. Rev. Drug Discov.* **2006**, 5, 813–814.
- [9] Culhane, N. S.; Lettieri, S. L.; Skae, J. R. Rosuvastatin for the treatment of hypercholesterolemia. *Pharmacotherapy* **2005**, 25, 990–1000.
- [10] McKenney, J. M. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. *Am. J. Health Syst. Pharm.* **2005**, 62, 1033–1047.
- [11] Balanov, A.; Shenkar, N.; Niddam-Hildesheim, V. Preparation of rosuvastatin. US Patent Application 7,167,625, 2007. *Chem. Abstr.* **2007**, 147, 166109.
- [12] Joshi, N.; Khile, A. S.; Kajale, Y. B.; Kamble, H. H. A process for the preparation of intermediates of rosuvastatin. WO 2008/059519 A2, **2008**.
- [13] Andrushko, N.; Andrushko, V.; König, G.; Spannenberg, A.; Börner, A. A new approach to the total synthesis of rosuvastatin. *Eur. J. Org. Chem.* **2008**, 5, 847–853.
- [14] Sterk, D.; Casar, Z.; Jukic, M.; Kosmrlj, J. Concise and highly efficient approach to three key pyrimidine precursors for rosuvastatin synthesis. *Tetrahedron* **2012**, 68, 2155–2160.
- [15] Kumar, Y.; De, S.; Rafeeq, M.; Meeran, H. N. P.N.; Sathyanarayana, S. Process for the preparation of rosuvastatin. WO 2003/097614 A2, **2003**.
- [16] Dijkman, A.; Marino-González, A.; Mairata i Payeras, A.; Arends, I. W. C. E.; Sheldon, R. A. Efficient and selective aerobic oxidation of alcohols into aldehydes and ketones using ruthenium/TEMPO as catalytic system. *J. Am. Chem. Soc.* **2001**, 123, 6826–6833.
- [17] Gamez, P.; Arends, I. W. C. E.; Reedijk, J.; Sheldon, R. A. Copper(II)-catalysed aerobic oxidation of primary alcohols to aldehydes. *Chem. Commun.* **2003**, 19, 2414–2415.
- [18] Iwahama, T.; Yoshino, Y.; Keitoku, T.; Sakaguchi, S.; Ishii, Y. Efficient oxidation of alcohols to carbonyl compounds with molecular oxygen catalyzed by *N*-hydroxyphthalimide combined with a Co species. *J. Org. Chem.* **2000**, 65, 6502–6507.
- [19] Greene, J. F.; Hoover, J. M.; Mannel, D. S.; Thatcher, R. W.; Stahl, S. S. Continuous-flow aerobic oxidation of primary alcohols with a copper(I)/TEMPO catalyst. *Org. Process Res. Dev.* **2013**, 17, 1247–1251.
- [20] Jing, Y. Y.; Jiang, J.; Yan, B.; Lu, S.; Jiao, J. M.; Xue, H. Z.; Yang, G. Y.; Zheng, G. X. Activation of dioxygen by cobaloxime and nitric oxide for efficient TEMPO-catalyzed oxidation of alcohols. *Adv. Synth. Catal.* **2011**, 353, 1146–1152.